Clinical Trials on Overactive Bladder Syndrome (OABS) in Netherlands

Total 50 results

Maastricht University Medical Center
University Hospital, Antwerp; Zuyderland Hospital

Unknown

Experience Sampling Method in OAB Patients

Overactive Bladder | Overactive Bladder Syndrome

Netherlands
Radboud University Medical Center

Withdrawn

Overactive Bladder (OAB) Drink Advice Study

Overactive Bladder Syndrome

Netherlands
Maastricht University Medical Center

Unknown

The Effect of Position on Urge Sensation in Volunteers and in Patients With Overactive Bladder Syndrome

Overactive Bladder Syndrome

Netherlands
Maastricht University Medical Center

Unknown

Non-Micturation Bladder Activity in Relation to Self-Consciousness During Filling Phase and Sensation Measurement During the Filling Phase

Lower Urinary Tract Symptoms | Overactive Bladder Syndrome

Netherlands
Maastricht University Medical Center

Completed

Basic Sensations Coming From the Bladder

Healthy | Overactive Bladder Syndrome

Netherlands
Maastricht University Medical Center

Completed

Effect of Pulse Rate Changes on Clinical Outcome

Overactive Bladder Syndrome | Chronic Urinary Retention

Netherlands
Avera Pharmaceuticals

Terminated

Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity

Overactive Bladder Syndrome

Netherlands, United Kingdom
BlueWind Medical

Recruiting

BlueWind RENOVA iStim™ System for the Treatment of OAB (OASIS)

Treatment of Patients Suffering From Overactive Bladder (OAB)

United States, Belgium, Netherlands, United Kingdom
Astellas Pharma Europe Ltd.

Terminated

An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics

Overactive Bladder | Healthy Subjects

Netherlands
Pfizer

Completed

Fesoterodine "add-on" Male Overactive Bladder Study

Overactive Bladder Syndrome

United States, Canada, Greece, Brazil, Korea, Republic of, Singapore, Poland, India, Norway, Slovakia, Spain, Belgium, Philippines, Netherlands, Sweden, Thailand, Malaysia, Germany, Colombia
Maastricht University Medical Center
Scientific Foundation Urology Maastricht

Completed

Screening Method in Sacral Neuromodulation

Overactive Bladder | Urinary Retention

Netherlands
Maastricht University Medical Center

Completed

Time of Effect Onset in Treating Overactive Bladder or Non Obstructive Urinary Retention by Sacral Neuromodulation

Overactive Bladder | Non Obstructive Urinary Retention

Netherlands
Axonics Modulation Technologies, Inc.

Completed

Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System (RELAX-OAB) (RELAX-OAB)

Overactive Bladder

Netherlands, France, Belgium, United Kingdom
Neuspera Medical, Inc.

Completed

Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence

Overactive Bladder

Netherlands
Radboud University Medical Center

Completed

Urgent-SQ in Treatment of Overactive Bladder Syndrome: 9-yr Follow up

Overactive Bladder | Urinary Incontinence, Urge | Urinary Frequency or Urgency Adverse Event

Netherlands
Astellas Pharma Inc

Completed

Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder

Overactive Bladder | Neurogenic Detrusor Overactivity

Belgium, Canada, Denmark, Netherlands, Poland, Turkey, United Kingdom
Sanofi

Completed

SSR240600C Treatment in Women With Overactive Bladder (BILADY)

Overactive Bladder

France, Germany, Netherlands, Portugal, Czech Republic, United States, Canada
MedtronicNeuro

Completed

InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study (BASIC)

Overactive Bladder | Urgency-frequency Syndrome | Urinary Urge Incontinence

United States, Netherlands, Canada, United Kingdom
MedtronicNeuro

Terminated

Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder (ACCEPTANCE)

Urinary Incontinence | Detrusor Overactivity | Neurogenic Overactive Bladder

Belgium, France, United Kingdom, Germany, Italy, Netherlands
Allergan

Completed

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Overactive Bladder

Portugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
BlueWind Medical

Completed

BlueWind Medical System for the Treatment of Patients With OAB (OAB)

Over Active Bladder

Netherlands, United Kingdom
Maastricht University Medical Center

Unknown

Brain Areas Involved in Bladder Filling and Contraction

Urinary Bladder, Overactive

Netherlands
Bayer

Completed

A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)

Overactive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic Cough

Netherlands
Ipsen

Terminated

Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder

Overactive Bladder

United Kingdom, Spain, Netherlands, Belgium, France, Germany, Czechia, Italy
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions

Neurogenic Urinary Bladder | Neurogenic Bladder Disorder | Neurogenic Dysfunction of the Urinary Bladder | Neurogenic Bladder, Uninhibited | Neurogenic Bladder, Spastic

Netherlands, Germany, Switzerland
Radboud University Medical Center
Astellas Pharma Inc; Continentie Stichting Nederland (Continence Foundation...

Unknown

Study of Overactive Bladder in Women With Prolapse (SOAP)

Urinary Bladder, Overactive | Pelvic Organ Prolapse

Netherlands
Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Ono Pharmaceutical Co. Ltd

Completed

Study of ONO-8539 in Patients With Overactive Bladder

Overactive Bladder

Poland, Ukraine, Romania, Russian Federation, Czech Republic, Hungary, Netherlands, Sweden, Germany
Allergan

Terminated

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

Urinary Incontinence | Urinary Bladder | Overactive

United States, Australia, Belgium, Canada, Czechia, France, Germany, Italy, Netherlands, Norway, Poland, South Africa, United Kingdom
Astellas Pharma Europe B.V.

Completed

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (SYNERGY)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

United States, Argentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands and more
Astellas Pharma Europe B.V.

Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (SYNERGY II)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

Belgium, Russian Federation, Korea, Republic of, United States, Germany, Spain, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, ... and more
GlaxoSmithKline

Completed

Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms

Overactive Bladder

Germany, Taiwan, Netherlands, Spain, Australia, Korea, Republic of, Latvia, Argentina, Slovenia, Finland, France, South Africa, Poland, New Zealand
Bayer

Completed

A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function

Overactive Bladder | Detrusor Overactivity

Spain, Belgium, Canada, Netherlands, Switzerland, Russian Federation, Germany, Israel, Hungary, Portugal, France, Poland, Czech Republic
Allergan

Completed

Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

Urinary Bladder, Overactive

France, United States, Netherlands
Allergan

Completed

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

Overactive Bladder

Poland, United Kingdom, Portugal, South Africa, Ukraine, Australia, Netherlands, Canada, Singapore, Russian Federation, Germany, Brazil, Austria, Slovakia, Czechia, United States, Taiwan, Italy, France, Belgium, Spain, New Zealand
Maastricht University Medical Center

Completed

Cohort Study: Perceptual Urge Sensation

Urinary Bladder, Overactive | Osteoporosis

Netherlands
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Overactive Bladder

Poland, United Kingdom, Germany, Spain, Netherlands, Belgium, Czech Republic, Italy, Norway, Hungary, Sweden, Denmark, Greece, France, Russian Federation
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) (SOLAR)

Overactive Bladder | Urinary Incontinence | Urge Incontinence

France, Belgium, Spain, Turkey, Australia, Russian Federation, Hungary, Italy, Netherlands, Poland, Czech Republic
MedtronicNeuro

Terminated

InterStim Micro Post Market Clinical Follow-up Study (ELITE)

Overactive Bladder | Fecal Incontinence | Non-obstructive Urinary Retention

United States, Netherlands, France, Canada, Switzerland, United Kingdom
Astellas Pharma Inc

Completed

Solifenacin Succinate Versus Tolterodine 4mg Once Daily (STAR)

Urinary Bladder, Overactive

France, United Kingdom, Spain, Belarus, Belgium, Ukraine, Denmark, Greece, Russian Federation, Czech Republic, Netherlands, Germany, Hungary, Italy, Slovakia, Sweden, Norway
Radboud University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development; IQ... and other collaborators

Recruiting

GAG-therapy Efficacy Trial Solution for Bladder Pain Syndrome/ Interstitial Cystitis (GETSBI Study) (GETSBI)

Bladder Pain Syndrome

Netherlands
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. (BEYOND)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases

Greece, Ireland, Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovaki... and more
Astellas Pharma Inc

Completed

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (SCORPIO)

Urinary Bladder, Overactive

Australia, Belgium, France, Spain, Sweden, Bulgaria, Romania, Italy, Greece, South Africa, Austria, Poland, United Kingdom, Hungary, Denmark, Netherlands, Switzerland, Ireland, Lithuania, Russian Federation, Germany, Latvia, Slovakia, Finlan... and more
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (Symphony)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases | Urological Manifestations | Signs and Symptoms

Belarus, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Astellas Pharma Inc

Completed

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (TAURUS)

Urinary Bladder, Overactive

Canada, Poland, Belgium, Spain, Sweden, United States, Romania, Italy, France, Austria, United Kingdom, Germany, Hungary, Australia, Denmark, Netherlands, Switzerland, Lithuania, Russian Federation, Latvia, South Africa, Slovakia, F... and more
Astellas Pharma Europe B.V.

Completed

A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis (SERENITY)

Interstitial Cystitis | Bladder Pain Syndrome

Spain, Russian Federation, Belgium, Czechia, Germany, Hungary, Latvia, Netherlands, Poland, United Kingdom
Aquinox Pharmaceuticals (Canada) Inc.

Unknown

Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome (LEADERSHIP 301)

Interstitial Cystitis | Painful Bladder Syndrome | Bladder Pain Syndrome | Chronic Interstitial Cystitis

United States, Belgium, Canada, Czechia, Denmark, Hungary, Latvia, Netherlands, Poland, Romania, Spain, United Kingdom
Coloplast A/S

Recruiting

INTIBIA Pivotal Study

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases | Lower Urinary Tract Symptoms | Urological Manifestations | Urinary Incontinence, Urge

United States, Netherlands
Ipsen

Terminated

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 (CONTENT1)

Overactive Bladder | Urinary Incontinence

United States, Korea, Republic of, Czechia, Netherlands, Romania, Poland, Turkey, Portugal, Canada, Italy
Astellas Pharma Europe B.V.

Completed

A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) (AMARANTH)

Pain | Urologic Diseases | Cystitis, Interstitial | Urinary Bladder Disease

Belgium, Czechia, Denmark, Germany, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russian Federation, Spain

Clinical Trials on Overactive Bladder Syndrome (OABS) in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations